As proof-of-principle, we focused our analysis on a series of major tumor antigens - BRAF, KRAS, HRAS, NRAS, TP53, CDK4, IDH1, TYR - which all carry recurrent oncogenic mutations. This evidence concerns the gene KRAS and neoplasm.